Werewolf Therapeutics Stock Investor Sentiment
| HOWL Stock | USD 1.09 0.04 3.54% |
About 52% of Werewolf Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Werewolf Therapeutics suggests that many traders are impartial. Werewolf Therapeutics' investing sentiment shows overall attitude of investors towards Werewolf Therapeutics.
Werewolf |
Werewolf Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Werewolf Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Werewolf Therapeutics that are available to investors today. That information is available publicly through Werewolf media outlets and privately through word of mouth or via Werewolf internal channels. However, regardless of the origin, that massive amount of Werewolf data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Werewolf Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Werewolf Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Werewolf Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Werewolf Therapeutics alpha.
Werewolf Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Seidel-dugan Cynthia of 79516 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Daniel Hicklin of 295500 shares of Werewolf Therapeutics subject to Rule 16b-3 | 12/26/2024 |
3 | Acquisition by Daniel Hicklin of 185652 shares of Werewolf Therapeutics at 1.56 subject to Rule 16b-3 | 01/02/2025 |
4 | Acquisition by Chulani Karunatilake of 103600 shares of Werewolf Therapeutics subject to Rule 16b-3 | 01/03/2025 |
5 | Acquisition by Daniel Hicklin of 592690 shares of Werewolf Therapeutics at 1.56 subject to Rule 16b-3 | 01/06/2025 |
6 | Werewolf Therapeutics stock hits 52-week low at 1.37 - Investing.com | 01/10/2025 |
7 | Werewolf Therapeutics Price Target Lowered to 4.00 at JMP Securities | 01/14/2025 |
8 | Arvinas, Inc. Reports Q4 Loss, Misses Revenue Estimates | 02/11/2025 |
9 | Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors | 02/24/2025 |
10 | Acquisition by Reid Leonard of 70967 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3 | 02/26/2025 |
11 | Pacira Tops Q4 Earnings Estimates | 02/27/2025 |
12 | Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference | 03/04/2025 |
13 | Werewolf Therapeutics Buy Rating Reiterated at HC Wainwright | 03/12/2025 |
14 | Werewolf Therapeutics Posts Earnings Results, Misses Estimates By 0.03 EPS | 03/13/2025 |
Check out Werewolf Therapeutics Hype Analysis, Werewolf Therapeutics Correlation and Werewolf Therapeutics Performance. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.63) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.